NLRP3 and acute kidney injury: Cilastatin was originally developed to inhibit the renal metabolism of imipenem by DHP-I, and it is not a known anti-inflammatory agent or direct ligand of TLR4 or NLRP3, although it protects against sepsis-induced AKI by decreasing inflammation.